bevacizumab,atezolizumab
roche
['imbrave050', 'hcc', 'atezo', 'rova,(-approval),(-microvascular)']
imbrave050 #aacr23 by pierce chow. ph 3, adj atezo-bev resected high risk hcc: mvi, macrovasc invasion vp1/vp2, tu &gt; 5cm, &gt; 3 lesions, grade 3/4 60% mvi, 52% tu &gt; 5cm, 7.5% vp1/vp2, 42% high grade. 1o endpoint: rfs mrfs: ne vs ne (hr 0.72; p 0.012) os immature. 
Medical Oncologist at BP Mirante Hospital. Former fellow at @HCBarretos. Focus in GI & GU Cancer. #PancSM #CRCSM #KCSM #GiCSM #GC #PCSM. Tweets are my own